SkyKick Releases Major Platform Upgrades with New Intelligent Cloud Backup Product, Revamped Security Manager, and Next-Generation Migration Suites
SkyKick (https://www.skykick.com), a global leader in cloud automation and management solutions for information technology service providers (ITSPs), today announced major enhancements to its Cloud Management Platform. New products and updates deliver enhanced data protection capabilities and personalized security insights, enabling ITSPs to meet the growing demand for robust security solutions and conversations in the SMB market. This marks the biggest platform update in the company’s ten-year history.
In an era dominated by data and AI, security is a top concern for 88% of SMB customers. Despite overall IT budgets staying flat or even declining, 42% of SMB business owners are open to investing more in security and data protection solutions. SMB appetite for MSP security services continues to grow against the backdrop of increased Microsoft 365 adoption (now with an estimated 382 million commercial users worldwide) and the proliferation of sensitive data that is being created in the cloud. ITSPs are struggling to meet demand.
“As pioneers in Microsoft 365 cloud data protection and security, we closely monitor usage and adoption trends among customers and partners," said SkyKick Co-CEO Todd Schwartz. "We’re seeing that in order for ITSPs to turn customer appetite into a successful security and data protection business, they need better and more intelligent tools. Our new products make it easy for ITSPs to not only meet customer demand, but also build a successful security practice – one that is easy to sell and easy to manage."
SkyKick is announcing a reimagined Cloud Backup product, offering Intelligent Data Protection for Microsoft 365. Among the exciting new features is SmartInsights, a new capability that enhances customer engagements through insights on data growth and protection trends. Today, customers are proactively seeking to understand their data protection status. With SmartInsights, ITSPs can tap into this customer appetite and transform data protection into a valuable differentiator.
Beyond SmartInsights, the new Cloud Backup introduces a user-centric architecture that streamlines ease of use for ITSPs. Examples include a new Groups Management functionality, which scales onboarding and offboarding processes. Extending the comprehensive Microsoft 365 coverage, protection for Microsoft Planner data is now also included. Collectively, the new Cloud Backup reimagines data protection for the modern ITSP, reducing time to resolution and increasing customer satisfaction.
Additionally, SkyKick has revamped its Security Manager solution, which now has millions of SMB end-users under management since its debut in the fall of 2022.
“For partners to fully deliver on the customer promise, they need to go beyond data protection. We created Security Manager to help partners be more proactive on security and grow a stronger practice,” said SkyKick Co-CEO Evan Richman. “Today, SkyKick is announcing SecurityRadar, a key innovation within Security Manager, purpose-built to arm 100,000 Microsoft cloud partners with data-driven security insights they can use to drive proactive and personalized customer engagement.”
Beyond SecurityRadar, Security Manager is upgrading its proprietary Microsoft Partner Center Connector (PCI) with new sync technology that is 2X faster and more automated - further simplifying day-to-day customer management and Microsoft-mandated GDAP compliance.
Early market reaction to the new updates has been very positive.
“Security is a top priority for Kinetix and New Charter Technologies. We are excited about the new innovations in Security Manager, and SecurityRadar is a game-changer for us,” said Robert Herbaugh, Security and Strategy Specialist at a leading MSP. “By facilitating strong customer conversations on security, it is helping us drive increased customer value and revenue growth.”
SkyKick is also announcing the next major version of its industry-leading Migration Suites. Between a streamlined setup, a more performant sync technology, and a highly configurable new migration experience – SkyKick has reimagined the “easiest way to Microsoft 365” with even more ease, flexibility, and control for the modern ITSP.
ITSPs, as well as their customers, deserve the assurance of knowing that their technology itself is certified to be robust and enterprise-grade. Building on its numerous other certifications, the SkyKick platform and system is now certified for ISO 27001, ISO 27701 and Data Pro.
SkyKick Co-CEO Evan Richman noted, “Our fundamental vision remains to be the platform of choice for ITSPs building and growing a business around Microsoft 365. With the major enhancements that we are announcing now across Migrations, Backup, Security Manager, and Certifications, we are confident that SkyKick will help IT partners to stay ahead of challenges and deliver a truly differentiated value in the channel.”
About SkyKick
SkyKick is a global provider of cloud management software for IT Services Providers. The company is headquartered in Seattle, Wash., and has offices in Amsterdam, Sydney, and Tokyo. Its products are designed to help build successful cloud businesses by making it easy and efficient for IT providers to migrate, backup, manage and secure their customers in the cloud. Over 30,000 partners worldwide use SkyKick’s products to accelerate their cloud business, and the company has won numerous awards including being named a Microsoft Partner of the Year, 2023 IAMCP Partner of the Year, Red Herring Top 100 North America winner and one of the “100 Best Companies to Work For” in Washington State. For more information visit www.skykick.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230727023626/en/
Contact information
Paul Forecki
Voxus PR for SkyKick
skykickpr@voxuspr.com
253.208.3615
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 10:05:00 EET | Press release
TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver
RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge ® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 10:00:00 EET | Press release
Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support commercial manufacturing of Omisirge® for this additional indication at its state-of-the-art cGMP cell therapy manufacturing facility in Hopkinton, MA. “We are excited to expand our collaboration with RoslinCT to add US manufacturing as Omisirge® moves into its next phase with the recent FDA approval for patients suffering from severe apl
Echoworx Secures FSQS-Netherlands Certification, Strengthening Trust in Financial Data Protection16.12.2025 08:00:00 EET | Press release
Echoworx, a global leader in email and data encryption, proudly announces it has achieved Financial Services Qualification System (FSQS) registered supplier status for the Netherlands. This certification powerfully demonstrates Echoworx’s commitment to the highest standards of security and compliance. This achievement expands on the company’s existing FSQS certification for the UK and Ireland, secured in 2020. By successfully completing the rigorous qualification for the Netherlands, Echoworx reinforces its alignment with the stringent demands of the European financial market. The FSQS system, managed by Hellios, provides a single, reliable standard for vetting third-party suppliers, streamlining procurement for major banks and financial institutions. Think of FSQS as a high-security passport for technology partners. It proves a supplier has undergone an exhaustive audit of its governance, security controls, and operational processes. For Dutch financial institutions, this qualificatio
Nippon Electric Glass to Start World’s First Mass Production of Low-Carbon Pharmaceutical Glass Tubing Using an All-Electric Furnace16.12.2025 04:00:00 EET | Press release
Nippon Electric Glass Co., Ltd. (NEG)(TOKYO:5214), a global leader in specialty glass headquartered in Otsu, Japan, announced it will begin the world’s first mass production of pharmaceutical-grade glass tubing using an all-electric melting furnace. Commercial production is scheduled to start in December 2025 at its subsidiary in Selangor, Malaysia. This breakthrough introduces a new manufacturing model for pharmaceutical packaging. By combining NEG’s proprietary all-electric melting technology with renewable energy, CO2 emissions from glass tubing production can be reduced by up to 90%*1 compared with conventional fossil-fuel combustion furnaces. This positions NEG as a major supplier capable of delivering both high-performance borosilicate glass and a significantly lower carbon footprint, directly addressing global sustainability demands from pharmaceutical companies and regulators. NEG is a leading global supplier of arsenic-free, environmentally friendly borosilicate glass tubing f
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform16.12.2025 03:00:00 EET | Press release
Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical’s HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP services, starting with high-yield exosome development using Esco Aster’s cell line platform. The technical reports of process, analytical, and formulation development, exosome drug loading, GMP engineering runs, and stability studies supported Shine-On’s IND submission. The IND was cleared by the U.S. FDA in Q1 2025. Furthermore, Esco Aster is providing technical services for exploratory exosome loading feasibility studies per Shine-On’s instruction. Shine-On Biomedical is an emerging innovator in exosome-based drug delivery. ShineOn’s proprietary product, SOB100, a HLA-G targeted exosome drug delivery carrier, has passed the U.S. FDA IND review and ongoing Phase I study, making it as a first-in-class–potential HLA-G targeted exosome platfo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom